Immunotherapy for treating SARS-CoV-2 and liver tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project explores two research lines: the first focuses on generating and characterizing human monoclonal antibodies against SARS-CoV-2 through in vitro functional tests. The second line evaluates the immune response efficacy mediated by antibodies targeting specific tumor molecules in liver tumors. The study aims to enhance understanding of immunotherapy's role in combating infectious and tumoral diseases. It is observational in nature, allowing for the collection of data without direct intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Line 1: - Age \>18 at time of signing informed consent form

* Signed informed consent form Line 2: - Primery liver tumor
* Age \>18 at time of signing informed consent form
* Signed informed consent form

Exclusion Criteria:

Line 1: - Active or history of neoplastic malignancy

* Active autoimmune disease ongoing treatment with immunosuppressive therapy
* Evidence of positive HIV, HCV, HBV test
* Diabetes
* Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months
* Chronic autoimmune or inflammatory diseases
* Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies
* Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse
* HIV infection
* Failure to sign informed consent form

Where it's running

• Fondazione IRCCS Policlinico San Matteo di Pavia
  Pavia, Pavia, Italy Recruiting

Study contacts

• Study coordinator: Mario Mondelli, MD
• Email: m.mondelli@smatteo.pv.it
• Phone: +390382502639

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vaccine formulations containing mRNA-1273 and mRNA-1283 to see if they boost immunity and remain safe

  This study tests whether two mRNA vaccines that target SARS-CoV-2 can safely generate an immune response in older adults and people with risk factors.

  Recruiting at 5 sites Phase 4 ModernaTX, Inc. · Overland Park, Kansas and 4 other locations · NCT07863635

• Vaccine study to test mRNA-1283 in children and infants

  A vaccine study will test two dose levels of mRNA-1283 in kids from 6 months to under 12 years to see which dose works best, using mRNA-1273 as a comparison.

  Recruiting at 12 sites Phase 2 ModernaTX, Inc. · Ontario, California and 30 other locations · NCT07808697

• Secutrelvir for high-risk COVID-19 patients who are not in hospital

  This study tests whether secutrelvir can help nonhospitalized teens and adults with COVID-19 who are at high risk of getting worse.

  Recruiting at 38 sites Phase 3 Shionogi Inc. · Coral Gables, Florida and 50 other locations · NCT07743580

• Italian registry of techniques to grow the liver before surgery

  This project will see how hospitals across Italy use different techniques to make the liver grow before surgery for adults with liver tumors.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT07445412

• Kisspeptin to measure GnRH neuron function in people with and without post-COVID-19 syndrome

  We will give one intravenous kisspeptin dose and take frequent blood samples to see if people with post-COVID-19 syndrome have different GnRH/LH hormone responses than people who had COVID but did not develop long COVID.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07224490

• Evaluating a new treatment to prevent severe COVID-19 complications

  This study is testing a new treatment to see if it can help hospitalized COVID-19 patients avoid severe complications caused by inflammation.

  Recruiting at 3 sites Phase 1/2 Peaches Biotech · Alcalá de Henares, Madrid and 2 other locations · NCT06684379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.